Concepedia

Letrozole Therapy

Letrozole Therapy is a pharmacological intervention classified under ovulation induction agents, specifically distinguished by its mechanism as a selective aromatase inhibitor that reduces estrogen synthesis to enhance follicular development in women with ovulatory disorders.

1.2K

Publications

88.8K

Citations

6.7K

Authors

2K

Institutions

Publications per year

2017–2026

435

Variants

Letrozole Treatment

Parents

Publications

1.2K

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.9K citations

, , +17

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

M Baum, Aman U. Budzar, J Cuzick et al. · The Lancet · 2002 · 2K citations

, , +13

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

, , +17

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Matthew P. Goetz, Masakazu Toi, Mario Campone et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

, , +16

A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

New England Journal of Medicine · 2005 · 1.6K citations · Full text

, , +9

1–5 of 1.2K

Authors

6.7K

  1. EA
    Edith A. Perez

    Mayo Clinic in Florida, United States

    22 publications · 4K citations

    22

    h-index

  2. MD
    Mitch Dowsett

    Royal Marsden Hospital, United Kingdom

    25 publications · 3.2K citations

    21

    h-index

  3. RS
    Richard S. Finn

    University of California, Los Angeles, United States

    22 publications · 7.1K citations

    20

    h-index

  4. JN
    James N. Ingle

    Mayo Clinic, United States

    23 publications · 3.6K citations

    20

    h-index

  5. PE
    Paul E. Goss

    Massachusetts General Hospital, United States

    22 publications · 2.4K citations

    19

    h-index

1–5 of 6.7K

Institutions

2K

  1. Novartis (Switzerland)

    Basel, Switzerland

    34 h-index

    149 publications

    29.3K citations

  2. Pfizer (United States)

    New York, United States

    29 h-index

    153 publications

    27.9K citations

  3. Massachusetts General Hospital

    Boston, United States

    28 h-index

    79 publications

    9.2K citations

  4. The University of Texas MD Anderson Cancer Center

    Houston, United States

    24 h-index

    119 publications

    19.5K citations

  5. Dana-Farber Cancer Institute

    Boston, United States

    23 h-index

    132 publications

    10K citations

  6. Novartis (United States)

    New York, United States

    23 h-index

    68 publications

    11.2K citations

  7. Western General Hospital

    Edinburgh, United Kingdom

    23 h-index

    106 publications

    7.7K citations

  8. Mayo Clinic in Florida

    Jacksonville, United States

    23 h-index

    74 publications

    8.4K citations

1–8 of 2K

Venues

  1. Journal of Clinical Oncology

    99 publications · 17.7K citations

    51

    h-index

  2. Fertility and Sterility

    65 publications · 5.3K citations

    41

    h-index

  3. Breast Cancer Research and Treatment

    53 publications · 3.2K citations

    32

    h-index

  4. Annals of Oncology

    34 publications · 4.3K citations

    26

    h-index

  5. Clinical Cancer Research

    31 publications · 2.1K citations

    24

    h-index

1–5